H Weston

Princess Alexandra Hospital (Queensland Health), Brisbane, Queensland, Australia

Are you H Weston?

Claim your profile

Publications (3)7.14 Total impact

  • H Weston · V Cowell · K Grimmett · R Saal · M Jones · T Mills · D Gill · P Marlton · R Bird · P Mollee
    [Show abstract] [Hide abstract]
    ABSTRACT: Thrombotic events in essential thrombocythaemia (ET) are difficult to predict with current risk stratification based on age and prior history of thrombosis. We aimed to assess the predictive value of the JAK2 V617F mutation (JAK2) and spontaneous erythroid colony (SEC) growth for the development of thrombotic events post diagnosis in patients with ET. Consecutive patients with ET were retrospectively identified, and clinical and laboratory correlates were evaluated. Thrombotic events were categorized according to their occurrence at or prior to diagnosis (prior thrombosis), and any time post diagnosis of ET (subsequent thrombosis). JAK2 analysis was performed by allele-specific PCR on whole blood or bone marrow. A total of 62 patients was identified, median age 63 years; 67% (41/61) JAK2-positive and 47% (25/53) SEC-positive. Median follow-up was 33 months (range, 1 to 137). JAK2-positive patients showed a trend to increased prior thrombosis (27% vs 5%, P= 0.08), and a significant increase in the development of subsequent thrombosis (5-year event rate 31% vs 6%, P= 0.04), which persisted when stratified for a history of prior thrombosis (P= 0.04). Survival was not affected by JAK2 status. The SEC assay predicted an increased rate of baseline thrombosis (16% vs 0%, P= 0.04), but was not found to be predictive of any subsequent thrombotic events. Patients with ET who are JAK2-positive by whole blood allele-specific PCR appear to be at increased risk of thrombotic complications, which is independent of a prior history of thrombosis.
    No preview · Article · May 2011 · Internal Medicine Journal
  • [Show abstract] [Hide abstract]
    ABSTRACT: The optimal initial therapy for treatment of adult acute lymphoblastic leukemia is yet to be defined. Hyper-CVAD has become a widely used treatment for adult acute lymphoblastic leukemia, although publication of outcomes is largely limited to single-center experience. We performed a retrospective analysis of 63 patients treated with Hyper-CVAD at two Australian institutions between 1995 and 2007. Complete remission was obtained in 86% of patients, with an induction mortality of 8%. Treatment-related toxicity was high, resulting in premature cessation of planned treatment in 29% of patients achieving CR. Survival estimates were comparable to previously published experience, with estimated 5-year overall and progression-free survival of 48% and 42%, respectively. Allogeneic stem cell transplant was performed in 22% of patients in first complete remission, with encouraging survival outcomes (estimated 5-year overall survival 75%, progression free survival 82%). Hyper-CVAD is an effective and tolerable induction strategy for adult ALL, and is suitable for use prior to allogeneic stem cell transplant in first complete remission.
    No preview · Article · Jan 2011 · Leukemia & lymphoma
  • H Weston · S Just · B Williams · J Rowell · G A Kennedy

    No preview · Article · Feb 2009 · Haemophilia

Publication Stats

15 Citations
7.14 Total Impact Points


  • 2011
    • Princess Alexandra Hospital (Queensland Health)
      Brisbane, Queensland, Australia
  • 2009-2011
    • Royal Brisbane Hospital
      • Department of Haematology
      Brisbane, Queensland, Australia